- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cardiovascular Disease
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 7,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 103 more
- Conditions
- Overweight, Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 34
- States / cities
- Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 21
- States / cities
- Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Costa Mesa, California • Plantation, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more
- Conditions
- Obesity
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 46
- States / cities
- Costa Mesa, California • San Diego, California • Walnut Creek, California + 41 more
- Conditions
- Overweight, Obesity
- Interventions
- Cagrilintide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more
- Conditions
- Overweight, Obesity
- Interventions
- Cagrisema, Placebo CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Hawthorne, California + 22 more
- Conditions
- Overweight, Obesity, Type 2 Diabetes Mellitus
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Concord, California • Escondido, California • Fullerton, California + 39 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide 2.4 mg, Cagrilintide 2.4 mg, Placebo (semaglutide), Placebo (cagrilintide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Fresno, California • Los Alamitos, California + 19 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 18
- States / cities
- Fresno, California • Northridge, California • Miami, Florida + 14 more
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 25
- States / cities
- Concord, California • Fresno, California • Palm Springs, California + 22 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema, Placebo CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • San Diego, California • Spring Valley, California + 16 more
- Conditions
- Alcohol-related Liver Disease
- Interventions
- NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more
- Conditions
- Obesity, Overweight
- Interventions
- Cagrilintide, Placebo (matched to Cagrilintide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Walnut Creek, California • Fleming Island, Florida • Jacksonville, Florida + 8 more
- Conditions
- Obesity, Overweight
- Interventions
- NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- La Mesa, California • San Diego, California • Miami, Florida + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Interventions
- Cagrilintide, Placebo (matched to Cagrilintide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 18 more
- Conditions
- Obesity, Overweight
- Interventions
- Cagrilintide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Walnut Creek, California • Aurora, Colorado • Orlando, Florida + 6 more